Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2015

View Archived Issues

TGR-1202 enters phase I trial in solid tumors

Pembrolizumab active in patients with advanced biliary tract cancer

Neurocrine Biosciences begins phase II study of NBI-98854 in Tourette syndrome

Viking Therapeutics performs safety, tolerability and pharmacokinetic study for VK-5211

CXCR4-targeted radiotherapy with [177Lu]/[90Y]pentixather could be useful in multiple myeloma

Foamix initiates phase II trial of FMX-103 in papulopustular rosacea

Yabao Pharmaceutical licenses second diabetes candidate from Lilly

Anti-TNF antibody DLX-105 improves symptoms of Behcet's disease

OPA-15406 shows promise in phase II atopic dermatitis trial

Vitamin B12-PYY3-36 peptide conjugate reduces food intake in vivo

S-76892: a promising agent with procognitive and disease modifier properties

F-17475 is safer and more potent than ketamine in postoperative pain

Bayer Schering Pharma discloses MMP-12 inhibitors

X-Rx patents autotaxin inhibitors

Taisho Pharmaceutical presents orexin receptor antagonists

Syros Pharmaceuticals divulges CDK7 inhibitors

Acquisition and licensing agreements expand Novartis' immune-oncology pipeline

Brighton Biotech acquires license for MERS and SARS vaccines

Pfizer reports IRAK-4 inhibitors

Scancell updates pipeline progress

Biogen reports data from phase III trial of natalizumab in secondary progressive MS

Femtogenix launched to discover anticancer payloads

FDA approves Veltassa for hyperkalemia

AstraZeneca and Lilly expand immuno-oncology combination therapy collaboration

Autoimmune disease candidate ARGX-113 enters phase I trial in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...